Registration Dossier

Administrative data

Key value for chemical safety assessment

Effects on fertility

Link to relevant study records
Reference
Endpoint:
screening for reproductive / developmental toxicity
Remarks:
based on test type (migrated information)
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: see 'Remark'
Remarks:
This study was designed similar to guideline OECD 415 and was performed according to GLP guidelines, but was designated mainly to select dose levels for a subsequent definite reproduction study. No histological examination of the reproductive or other organs were performed.
Justification for type of information:
REPORTING FORMAT FOR THE ANALOGUE APPROACH
[Please provide information for all of the points below. Indicate if further information is included as attachment to the same record, or elsewhere in the dataset (insert links in 'Cross-reference' table)]

1. HYPOTHESIS FOR THE ANALOGUE APPROACH
[Describe why the read-across can be performed (e.g. common functional group(s), common precursor(s)/breakdown product(s) or common mechanism(s) of action]

It is hypothesized that the target chemical and the following chemicals as source chemicals should exhibit comparable toxicity profiles:
-6-(isononanoylamino)hexanoic acid, compound with 2,2`,2``-nitrilotriethanol
-3,5,5-trimethylhexanoic acid
It is proposed to use the toxicity data of the mentioned source chemicals to fulfill the data requirement for the target chemical. The first chemical is a salt of the target chemical. 3,5,5-trimethylhexanoic acid is a presumed metabolite.

The underlying scientific rationale for the use of corresponding salt as source chemical is apparent. The target chemical is a weak acid due to the terminal carboxylic acid moiety and can be neutralized/dissolved in aqueous system by reaction with base such as 2,2`,2``-nitrilotriethanol. The proposed source chemical can be formally described as carboxylate of the target chemical. As the carboxylate and carboxylic acid are inter-convertible, it is apparent that source and target chemicals are inter-convertible and should exhibit comparable toxicity profile. The base 2,2`,2``-nitrilotriethanol is a well-investigated substance and is considered to be less relevant for the proposed read-across consideration.

The underlying scientific rationale for the use of 3,5,5-trimethylhexanoic acid as source chemical is based on the metabolism consideration. Upon resorption, the target chemical is expected to undergo a degradation process, resulting in the systemic release of 3,5,5-trimethylhexanoic acid, thereby providing the justification for the read-across especially for the mid- and long term toxicities such as repeated dose toxicity and reproduction toxicity.

The proposed approach applies for all exposure routes (oral/dermal/inhalation), because both the target chemical and source chemicals are expected to be bioavailable by all exposure routes: the inter-conversion between carboxylic acid and carboxylate is likely to occur prior to resorption; and the systemic release of the presumed metabolite is less dependent on exposure route.

2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
[Provide here, if relevant, additional information to that included in the Test material section of the source and target records]

Target chemical:
6-(Isononanoylamino)hexanoic acid; CAS: 71902-23-3
Source chemicals:
6-(isononanoylamino)hexanoic acid, compound with 2,2`,2``-nitrilotriethanol; CAS: 85702-79-0
3,5,5´-trimethylhexanoic acid; CAS: 3302-10-1

The target chemical is a mono-substituent substance, the analytical purity being >99%. The source chemicals are either the raw material (3,5,5´-trimethylhexanoic acid) or further chemically processed products (dissolved in water with 2,2`,2``-nitrilotriethanol) of the target chemical. A toxicity difference due to different impurity profiles is not likely to occur.

3. ANALOGUE APPROACH JUSTIFICATION
[Summarise here based on available experimental data how these results verify that the read-across is justified]

Justification for the use of 6-(isononanoylamino)hexanoic acid, compound with 2,2`,2``-nitrilotriethanol as source chemical:

- The given source chemical is an ionic compound that results from the neutralization reaction of the target chemical and 2,2`,2``-nitrilotriethanol. When it is dissolved in an aqueous system or in a biological fluid, an immediate dissociation occurs to give the target chemical and the base, thereby explaining the expected comparable toxicity profile to that of target chemical.
A significant toxicity contribution of 2,2`,2``-nitrilotriethanol is not expected. 2,2`,2``-nitrilotriethanol is a well investigated substance. It is of low toxicity and the available kinetic data are demonstrative of efficient elimination mechanisms in animal models.
- In order to verify the expected toxicity comparability, the given source and the target chemicals were investigated under identical testing conditions. Both substances exhibited comparable findings after 7-day oral application to rat:
-liver and kidney enlargement
-decrease of eosinophil counts
-peroxisome proliferation in the liver
The decrease of eosinophil counts is possibly a transient effect, associated with the peroxisome proliferation stimulating effect of test compounds. No such findings were present after 28-day treatment of the source chemical.
- Comparable findings were obtained in the 28-day oral toxicity study for the given source chemical and in the above mentioned two 7-day repeated oral toxicity studies. Further special histopathological investigation revealed the alpha-2µ-globulin accumulation in male kidneys and the peroxisome proliferation in liver.
- In the available skin sensitization data the given source chemical was applied using water as vehicle. The dissociation into the target chemical and 2,2`,2``-nitrilotriethanol is expected to have occurred prior to resorption, so that the animals must have been exposed to the target chemical.

Justification for the use of 3,5,5-trimethylhexanoic acid as source chemical:

- 3,5,5-trimethylhexanoic acid is the presumed metabolite. It is also the presumed metabolite of 6-(isononanoylamino)hexanoic acid, compound with 2,2`,2``-nitrilotriethanol.
This view is based on the results of the metabolites investigation in degradation samples obtained in a Zahn-Wellens test. The ß-oxidation at the terminal carboxylic acid moiety in combination with hydrolysis at amide bond could be assumed as the degradation pathway leading to 3,5,5-trimethylhexanoic acid as a stable metabolite.
Also the hydrolysis at the amide moiety is thinkable. The hydrolysis products would be then 3,5,5-trimethylhexanoic acid and 6-aminocaproic acid. The latter compound is a drug known as amicar and is expected to be far more rapidly eliminated than 3,5,5-trimethylhexanoic acid. A significant toxicity attribution of 6-aminocaproic acid cannot be derived.
One literature article was found, describing further biotransformation of 3,5,5-trimethylhexanoic acid in rat: gamma-lactone of 3,5,5-trimethylhexanoic acid is formed, which may be the ultimate toxicant for the alpha-2µ-globulin accumulation in kidneys
- The findings in the 28-day oral toxicity study on the 3,5,5-trimethylhexanoic acid are comparable to those found in the repeated dose toxicity studies of the target chemical and 6-(isononanoylamino)hexanoic acid, compound with 2,2`,2``-nitrilotriethanol:
- liver and kidney enlargement
- peroxisome proliferation in the liver
- The alpha-2µ-globulin accumulation in kidneys.


4. DATA MATRIX

Data matrix and other information see the attached read-across justification in chapter 13
Qualifier:
equivalent or similar to
Guideline:
OECD Guideline 415 [One-Generation Reproduction Toxicity Study (before 9 October 2017)]
Deviations:
yes
Remarks:
no histological examinations
Principles of method if other than guideline:
one generation range-finding study similar to guideline OECD 421 and performed according to GLP guidelines. No histological examination of the reproductive or other organs were performed.
GLP compliance:
yes
Limit test:
no
Species:
rat
Strain:
other: Crl:CDBR
Sex:
male/female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Charles River Inc., males: Raleigh, NC, USA, females: Stone Ridge, NY, USA
- Age at study initiation: (P) approx. 7 wks
- Weight at study initiation: (P) Males: 221-266 g; Females: 168-201 g
- Housing: individual, except the mating and post partum periods
- Diet: PMI Certified Rodent Diet Meal 5002 ad libitum
- Water: ad libitum
- Acclimation period: 13 days


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24,4
- Humidity (%): 40-70
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12 h/12 h
Route of administration:
oral: feed
Details on exposure:
PREPARATION OF DOSING SOLUTIONS: undiluted test substance used

DIET PREPARATION
- Rate of preparation of diet (frequency): weekly (first 5 weeks), twice weekly (therafter)
- Mixing appropriate amounts with (Type of food): basal diet
- Storage temperature of food: room temperature

Details on mating procedure:
- M/F ratio per cage: 1/1
- Length of cohabitation: overnight
- Proof of pregnancy: vaginal plug and/ or sperm in vaginal smear, referred to as day 0 of pregnancy
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
All meal samples were within 10% of nominal concentration; stable for at least 4 days at 0.06% concentration, for at least 15 days at higher concentrations, details given in Appendix W
Duration of treatment / exposure:
P1 males and females were both exposed for at least 10 weeks proir to mating, through the mating period. Males were further exposed until their sacrifice, females throughout gestation and lactation until day 28 post partum. F1 pups were exposed from day 28 post partum until their sacrifice (postnatal day 42 (females) to 49 (males)).
Frequency of treatment:
daily, via feed
Remarks:
Doses / Concentrations:
0.06, 0.12, 0.25 and 0.5%
Basis:
nominal in diet
No. of animals per sex per dose:
10
Control animals:
yes, plain diet
Parental animals: Observations and examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Cageside observations were performed daily on all P1 adults and after weaning for all F1 offspring, except the days clinical observations were performed.

VIABILITY: Yes
-Tiime schedule: All animals were examined for viability at least twice daily Monday through Friday, and at least once daily on weekends and holidays.

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: A clinical examination was given to each male prior to P1 selection, on the first day of dosing, and at least weekly thereafter until euthanized. Females received a clinical examination prior to P1 selection, on the first day of dosing, and at least weekly thereafter until confirmation of mating, then on GD 0, 7, 14, and 21, and on PPD 0, 4, 7, 14 and 21.


BODY WEIGHT: Yes
- Time schedule for examinations: Body weights were recorded for all females pretest, at initiation of dosing (Day 0), on Days 4 and 7, and weekly until confirmation of mating or the end of the mating period. Body weights were recorded for confirmed-mated females on GDs 0, 7, 14, and 21, on PPDs 0, 4, 7, 14, and 21 and weekly after Postpartum Day 21. After the mating period, body weights were recorded weekly for females not confirmed mated until they were sacrificed. Confirmed-mated females which did not deliver by GD 26 were weighed weekly after GD 26 until sacrificed. Body weights also were recorded on the day of sacrifice for all females.


FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
Food consumption was measured on Days 1, 2, 3, and 7, and then concurrently with body weight after Day 7, except during the mating period and on GD 0 and PPD 0 for the females when food consumption was not measured.
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No


OTHER:
- signs of parturition were examined at least twice daily beginning on gestational day (GD) 21. The duration of gestation was calculated and any difficulties occurring at parturition were noted. The date of parturition was recorded as the dam's Postpartum Day 0 (PPD 0).

POSTNATAL EXAMINATION: Yes
Each morning and afternoon during the postnatal period, the litters were checked for dead offspring and unusual conditions, and the dams were examined for viability, nesting, and nursing behavior.
Dead pups were removed from the litter immediately after their discovery. If intact, dead pups were examined externally and internally for anomalies. Dead pups discovered on PND 0 also were examined internally to determine whether they were stillborn.
On PND 0, 1, 4, 7, 14, 21, and 28 the offspring were counted, sexed, and each live pup was weighed. Pups were counted and examined externally on a daily basis during the postnatal period. All animals were weighed on PND 35, 42, and 49 (males only were weighed on PND Day 49).
On PND 4, after counting, weighing, and examining the pups, the size of each litter was adjusted by eliminating extra pups by random selection to yield, as nearly as possible, 4 males and 4 females per litter. Partial adjustment (e.g., 5 males and 3 females) was permitted whenever there were not enough pups to obtain 4 per sex per litter. Litters of eight pups or less were not adjusted.
Culled pups were sacrificed. Culled pups that appeared normal received only an external examination and tissues were not saved. Culled pups that appeared abnormal were subjected to a visceral examination.
The pups from each litter were examined daily for pinna detachment (starting PND 1), hair growth (starting PND 3), righting reflex (starting PND 3), incisor eruption (starting PND 7), and eye opening (starting PND 11). The examinations continued for an individual landmark until the criterion for that landmark was attained. Additionally, beginning on PND 29, all surviving female offspring were examined daily for vaginal opening. Beginning on PND 35 all surviving male offspring were examined daily for preputial separation. The examinations continued until all animals reached criteria.

Oestrous cyclicity (parental animals):
Vaginal smears were performed on each female on their day of sacrifice to determine its stage in the estrous cycle. The stage of the estrous cycle was recorded, but not used for estrous cycle calculations.
Sperm parameters (parental animals):
Samples of sperm from the left distal cauda epididymis (or proximal vas deferens) were collected at necropsy and evaluated for the percentage of progressively motile sperm and sperm morphology. Also, the entire left cauda epididymis was minced in saline to enumerate the total number of sperm (cauda reserves).
Litter observations:
Each morning and afternoon during the postnatal period, the litters were checked for dead offspring and unusual conditions, and the dams were examined for viability, nesting, and nursing behavior.
Dead pups were removed from the litter immediately after their discovery. If intact, dead pups were examined externally and internally for anomalies. Dead pups discovered on PND 0 also were examined internally to determine whether they were stillborn.
On PND 0, 1, 4, 7, 14, 21, and 28 the offspring were counted, sexed, and each live pup was weighed. Pups were counted and examined externally on a daily basis during the postnatal period. All animals were weighed on PND 35, 42, and 49 (males only were weighed on PND Day 49).
On PND 4, after counting, weighing, and examining the pups, the size of each litter was adjusted by eliminating extra pups by random selection to yield, as nearly as possible, 4 males and 4 females per litter. Partial adjustment (e.g., 5 males and 3 females) was permitted whenever there were not enough pups to obtain 4 per sex per litter. Litters of eight pups or less were not adjusted.
Culled pups were sacrificed. Culled pups that appeared normal received only an external examination and tissues were not saved. Culled pups that appeared abnormal were subjected to a visceral examination.
The pups from each litter were examined daily for pinna detachment (starting PND 1), hair growth (starting PND 3), righting reflex (starting PND 3), incisor eruption (starting PND 7), and eye opening (starting PND 11). The examinations continued for an individual landmark until the criterion for that landmark was attained. Additionally, beginning on PND 29, all surviving female offspring were examined daily for vaginal opening. Beginning on PND 35 all surviving male offspring were examined daily for preputial separation. The examinations continued until all animals reached criteria.
Postmortem examinations (parental animals):
Gross necropsies were performed on all adult animals that were found dead. Body weight was recorded on the day of necropsy. The uterus of each female used for mating, but failing to deliver, was examined grossly for evidence of implantations and these data were recorded.
A gross necropsy was performed on all adult animals surviving to termination. Body weights were recorded on the day of necropsy. The uterus of each female was examined grossly for evidence of implantation and the number of implantation sites was recorded.

The following tissues and organs of all males surviving to termination and all females were weighed prior to fixation:
ovaries (individual) uterus
testes (individual) prostate
liver
right epididymis (total and cauda)
seminal vesicles (with coagulating glands and their fluids)

The following organs and tissues of all adults were preserved in 10% neutral buffered formalin:
coagulating gland right epididymis
seminal vesicles prostate
testes* uterus
liver ovaries
*:The right testis was preserved in Bouin's solution. The right testis remained in Bouin's solution for approximately 24 hours. The right testis was then rinsed with tap water and stored in 70 percent Ethyl Alcohol. The left testis was frozen for enumeration of homogenization resistant spermatids.

Abnormal tissues were preserved in 10% neutral buffered formalin at the discretion
of the Study Director or designee for possible future microscopic examination.
Postmortem examinations (offspring):
Intact dead pups or pups sacrificed in moribund condition on PND 0 were examined by fresh visceral dissection. Dead pups and pups sacrificed as moribund after PND 0 were examined externally for anomalies and internally for gross visceral abnormalities. Culled pups (PND 4) with external abnormalities were subjected to a visceral examination at the discretion of the Study Director or his designee.
Statistics:
Group means and standard deviations were calculated.
Reproductive indices:
mean male fertility and mating indices and female fertility, fecundity and gestational indices
Offspring viability indices:
offspring survival
Clinical signs:
no effects observed
Body weight and weight changes:
effects observed, treatment-related
Food consumption and compound intake (if feeding study):
effects observed, treatment-related
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Gross pathological findings:
no effects observed
Histopathological findings: non-neoplastic:
not examined
Other effects:
effects observed, treatment-related
Reproductive function: oestrous cycle:
not examined
Reproductive function: sperm measures:
no effects observed
Reproductive performance:
no effects observed
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
Significant increases in body weight gain in males of the 0.12 and 0.5% dose groups were considered incidental and unrelated to treatment with the test material (absence of a clear consistent response over the test period).
Statistically significantly decreased mean body weights when compared with controls were observed in the 0.5% females on Gestation Day (GD) 7 (9%) and on GD 21 (11%) and on Postpartum Days (PPD) 4, 7, and 14 (17%, 12%, and 10%, respectively). Also, there was a corresponding statistically significant decrease in mean body weight change for the 0.5% group females at the PPD 0-4 interval (209%). There also was a statistically significantly decreased mean body weight compared with controls in the 0.25% females on PPD 4 (10%).
There also were statistically significant increases in mean body weight change in the 0.25 and 0.5% group females at the PPD 4/7 (470% and 567%, respectively), PPD 14/21 (154% and 235%, respectively), and in the 0.25% females on PPD 0/21 intervals (112%).
There were statistically significant decreases in mean food consumption for the 0.5% group males at Days 1 (2 1%) and 2 (2 1%). There were statistically significant decreases in mean food consumption in the 0.25% group females at Day 1 (30%), Day 3 (18%), and Weeks 1 (13%), 2 (11%), 3 (21%), 4 (13%), and 6 (12%). There also were statistically significant decreases in mean food consumption for the 0.5% group females at Day 1 (47%) and Weeks 1 (15%), 2 (13%), 4 (11%), and 6 (10%). These decreases were considered to be due to reduced palatability of the diet mixtures.
There were no statistically significant differences in food consumption during the gestation period. However, statistically significant decreases in food consumption were noted in the 0.5% group females during the PPD 0/4 (46%), 7/14 (15%), and entire postpartum period (PPD 0-28) (17%).


ORGAN WEIGHTS (PARENTAL ANIMALS)
There were no statistically significant changes in the mean absolute or mean relative organ weights for the reproductive organs weighed during the study. There were statistically significant increases in the mean absolute and mean relative liver weights of the 0.5% males (15% and 21%, respectively) and 0.5% females (21% and 24%, respectively) and the 0.25% females mean absolute and relative liver weights (15% and 14%, respectively). The significance of the increases in the liver weights could not be determined because histopathology was not performed on the tissues.

REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS):
There was a statistically significant decrease in the mean percent live offspring (6%) and the corresponding increase in the mean percent dead offspring (700%) in the 0.5% dose group.

Dose descriptor:
LOAEL
Effect level:
165 - 500 mg/kg bw/day
Sex:
female
Basis for effect level:
other: decreases in body weight, increased liver weight; 0.25% in diet, calculated by the authors on the basis of food consumption and body weights
Dose descriptor:
NOAEL
Effect level:
79 - 228 mg/kg bw/day
Sex:
female
Basis for effect level:
other: 0.12% in diet, calculated by the authors on the basis of food consumption and body weights
Clinical signs:
no effects observed
Mortality / viability:
mortality observed, treatment-related
Body weight and weight changes:
effects observed, treatment-related
Sexual maturation:
no effects observed
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
no effects observed
Histopathological findings:
not examined
VIABILITY (OFFSPRING)
There were statistically significant decreases in 0.5% group offspring compared with the control offspring for the live birth index (6.0%), the Day 1 survival index (14%), and the Day 4 survival index (2 1%).

BODY WEIGHT (OFFSPRING)
There were statistically significant decreases in mean offspring body weights in the 0.25% group males and females at PND 0, 1, 4, 7, 35 and 42. There also were statistically significant decreases in mean offspring body weights in the 0.25% group males at PND14, 28, and 49.

SEXUAL MATURATION (OFFSPRING)
There was a statistically significant advance for preputial separation for the 0.06% group males (1.2 days) when compared with the controls. Due to the small size of this advance and the absence of a dose response, this difference was not considered biologically significant. There also was a statistically significant retardation of preputial separation for the 0.5% group males (2.1 days) compared with the control male offspring. In the females, the 0.5% group exhibited a statistically significant retardation (1.8 days) for vaginal patency compared with controls. These two findings are not biologically significant but rather reflect the normal maturation of these animals with the delays due to somewhat smaller body weights.

OTHER FINDINGS (OFFSPRING). DEVELOPMENTAL LANDMARKS
There were statistically significant retardations in the male eye opening for the 0.5% group (0.7 days later), and the male and female pinna detachment in the 0.5% group (1.0 day later each). These findings are not biologically significant but rather reflect the normal maturation of these animals with the delays due to somewhat smaller body weights.
Dose descriptor:
LOAEL
Generation:
F1
Effect level:
0.25 other: % in diet
Sex:
male/female
Basis for effect level:
other: reduced fetal weights, no calculation of body doses stated
Dose descriptor:
NOAEL
Generation:
F1
Effect level:
0.12 other: % in diet
Sex:
male/female
Basis for effect level:
other: no calculation of body doses stated
Reproductive effects observed:
not specified

BODY DOSES BASED ON FOOD CONSUMPTION AND BODY WEIGHTS

DOSE
(%)

WEEK 1
(mg/kg/day)

WEEKS 2-9
(mg/kg/day)

WEEK 10
(mg/kg/day)

Gestation

Postpartum

M

A

L

E
S

0.06

59

33-51

32

Not
Applicable

Not
Applicable

0.12

117

66-101

66

0.25

247

147-215

145

0.5

477

289-435

290

F
E

M A L E S

0.06

57

40-56

40

37-42

57-126

0.12

116

79-112

81

79-86

109-228

0.25

231

168-224

167

165-185

241-500

0.5

450

347-453

347

336-382

311-970

MEAN OFFSPRING BODY WEIGHT - F1 (PREWEANING)


}Group

MALE
PND 0

MALE
PND 1

MALE
PND 4

MALE
PND 7

MALE
PND 14

MALE
PND 21

MALE
PND 28

0%

6.71

7.09

9.54

15.58

32.32

51.18

91.53

0.06%

6.82

7.31

10.13

16.70

34.12

53.06

93.88

0.12%

6.39

6.85

9.01

14.44

30.72

48.88

90.23

0.25%

5.76**h

5.95**h

7.98*h

12.55**h

28.64*h

46.23

81.65**

0.5%

5.66**h

5.73**h

7.67**h

11.07**h

23.31**h

39.18**h

72.63**

Historical
Control

6.35-7.02

6.68-7.49

8.53-11.43

13.64-18.74

28.81-37.09

44.89-62.34

98.34

Group

FEMALE
PND 0

FEMALE
PND 1

FEMALE
PND 4

FEMALE
PND 7

FEMALE
PND 14

FEMALE
PND 21

FEMALE
PND 28

0%

6.36

6.89

9.33

14.72

30.50

47.77

82.46

0.06%

6.51

7.00

9.67

15.35

31.89

49.18

83.84

0.12%

5.92h

6.40

8.78

13.81

28.79

46.18

81.83

0.25%

5.46**h

5.65**h

7.83**h

12.77*h

28.89

45.33

77.09

0.5%

5.65**h

5.65**h

7.55**h

11.10**h

23.47**h

38.59**h

69.34**

Historical
Control

5.96-6.74

6.30-7.16

8.32-11.05

13.33-17.69

27.22-35.89

42.39-61.19

90.68

MEAN OFFSPRING BODY WEIGHT - F1 (POSTWEANING)

{ }Group

MALE
PND 35

MALE
PND 42

MALE
PND 49

0%

147.7

205.8

266.3

0.06%

151.0

211.4

272.4

0.12%

144.3

205.1

266.3

0.25%

128.4**

183.4**

242.1**

0.5%

119.8**

170.9**

227.6**

Group

FEMALE
PND 35

FEMALE
PND 42

FEMALE
PND 49

0%

124.8

158.3

NA

0.06%

126.5

161.4

NA

0.12%

123.1

157.2

NA

0.25%

114.9**

148.6*

NA

0.5%

109.3**

140.9**

NA

NOTE: All weights are in grams

* Mean significantly different from control mean (p0.05)

** Mean significantly different from control mean (p0.01)

NA not applicable

Conclusions:
Under the conditions of this study administration of the test substance resulted in evidence of maternal toxicity and findings in offspring that may have been secondary to maternal toxicity. Maternal toxicity was demonstrated by decreased body weight and food consumption during the gestation and postpartum periods, and increased absolute and relative liver weights in the 0.25% and 0.5% groups (79-228 and 165-500 mg/kg bw and day). Paternal effects were limited to increased absolute and relative liver weights in the 0.5% group. The differences between male and female adults in this study may be due to the somewhat higher dose rates observed in the females, especially during the postpartum period. Coincident with the maternal effects, offspring body weights were decreased in both sexes in the 0.25% and 0.5% groups, and offspring survival was decreased in the 0.5% dose group. There were also some small delays in developmental landmarks in the high dose offspring. These delays are likely secondary to the decreased offspring growth in this group.
There was no evidence of adverse effects on mating behavior, fertility, sperm parameters, or reproductive organ weights in the parental animals. Thus, the test material does not effect fertility at the dose levels tested. There were also no malformations observed in the offspring in this study. There were indications of offspring toxicity that may be related to maternal toxicity in the two highest doses. The apparent NOAEL for both maternal and offspring effects in this study is the 0.12% level.
Executive summary:

In this one-generation range-finding study (performed similar to OECD guideline 415) the test substance was administered to male and female rats in the diet (10 per sex and dose; 0.06, 0.12, 0.25 and 0.5% in diet) for at least ten weeks prior to mating and during the mating period. The dams were exposed during the gestation and postpartum periods, until weaning of the offspring on Postpartum Day (PPD) 28. The parental male animals were sacrificed at the end of the mating period, the females and the offspring after weaning.

Effects in the P-generation:

There were no treatment-related deaths, clinical signs or effects on male or female reproductive organ weights or reproductive parameters. Statistically significant decreases were observed in food consumption of the 0.5% group females at various postnatal timepoints. The body weights of the parental generation were reduced in females of the 0.25% group at PPD 4 as well as in 0.5% females at Gestation Days (GD) 7 and 21 and at PPD 4, 7, and 14. Liver weights were increased in males at 0.5%, in females at 0.25% and above.

Effects in offspring:

Reduced Live Birth Index and survival indices were observed in the 0.5% group. Postnatal offspring body weights of both sexes of the 0.25% and 0.5% groups were reduced compared with the controls.

No treatment-related clinical signs were noted for the offspring. A postnatal developmental delay was obvious in the 0.5% dose group offspring in form of delayed onset of eye opening in male offspring, pinna detachment in both sexes, retardation of preputial separation and vaginal patency. These delays were considered to be treatment-related and secondary to reduced offspring body weight.

No effects were observed with respect to fertility, thus the NOAEL for reproductive toxicity was 0.5% (highest tested dose, 289-477 mg/kg bw/day in males, 336-970 mg/kg bw/d in females for P generation). The LOAEL for systemic parental (female) and offspring toxicity was 0.25% (165 -500 mg/kg/bw/day for P generation), the NOAEL was 0.12% (79 -228 mg/kg bw/day for P generation)(Exxon, 1998).

This study, performed similar to OECD guideline 415, was judged to be reliable (RL2) and selected as key study.

Effect on fertility: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
289 mg/kg bw/day
Study duration:
subchronic
Species:
rat
Quality of whole database:
This one-generation study is reliable (Klimisch 2). The quality of the database is high.
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available
Additional information

A one generation range finding study (performed similar to OECD guideline 415) was performed with a surrogate for the submission substance. In this study the test substance was administered to male and female rats in the diet (10 per sex and dose; 0.06, 0.12, 0.25 and 0.5% in diet) for at least ten weeks prior to mating and during the mating period. The dams were exposed during the gestation and postpartum periods, until weaning of the offspring on Postpartum Day (PPD) 28. The parental male animals were sacrificed at the end of the mating period, the females and the offspring after weaning.

Effects in the P-generation: There were no treatment-related deaths, clinical signs or effects onmale or female reproductive organ weights or reproductive parameters. Statistically significant decreases were observed in food consumption of the 0.5% group females at various postnatal timepoints.The body weights of the parental generation were reduced in females of the 0.25% group at PPD 4 as well as in 0.5% females at Gestation Days (GD) 7 and 21and at PPD 4, 7, and 14. Liver weights were increased in males at 0.5%, in females at 0.25% and above.

No effects were observed with respect to fertility, thus the NOAEL for reproductive toxicity was 0.5% (highest tested dose, 289-477 mg/kg bw/day in males, 336-970 mg/kg bw/d in females). The LOAEL for systemic parental (female) was 0.25% (165 -500 mg/kg/bw/day), and thus the NOAEL was 0.12% (79 -228 mg/kg bw/day) (Exxon, 1998).

This study, performed similar to OECD guideline 415, was judged to be reliable (RL2) and selected as key study.


Short description of key information:
In a reliable one generation range finding study in rats (performed similar to OECD 415) with a surrogate of the submission substance, no effects on fertility were observed up to the highest dose tested. The NOAEL with respect to fertility is 0.5% in diet (i.e. 289-477 mg/kg bw/day for males and 336-970 mg/kg bw/day for females).
As there were other systemic effects not related to fertility in females the NOAEL for the parental generation for systemic effects is 0.12 % in diet (i.e. 79-228 mg/kg bw/day for females).

Justification for selection of Effect on fertility via oral route:
Only reliable study available conducted under GLP with a surrogate of the submission substance

Justification for selection of Effect on fertility via inhalation route:
no study required as the oral application route is expected to be the relevant exposure route for humans, due to the physical-chemical properties of the submission substance

Justification for selection of Effect on fertility via dermal route:
no study required as the oral application route is expected to be the relevant exposure route for humans, due to the physical-chemical properties of the submission substance

Effects on developmental toxicity

Description of key information
 In a reliable Prenatal Developmental Toxicity in rats (according to OECD 414) with a surrogate of the submission substance, there were no effects on maternal parameters as well as fetal parameters at all the tested dose groups. the NOAEL for the surrogate substance for maternal and developmental toxicity toxicity is 500 mg/kg bw.  Based on the analogue approach, the NOAEL of the subimission substance is also considered to be 500 mg/kg bw. No effects regarding developental toxicity are expected.
Link to relevant study records
Reference
Endpoint:
developmental toxicity
Type of information:
read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Study period:
03 September 2018 to 07 December 2019
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
guideline study
Remarks:
OECD414, adopted on 25 June 2018
Justification for type of information:
REPORTING FORMAT FOR THE ANALOGUE APPROACH
[Please provide information for all of the points below. Indicate if further information is included as attachment to the same record, or elsewhere in the dataset (insert links in 'Cross-reference' table)]

1. HYPOTHESIS FOR THE ANALOGUE APPROACH
[Describe why the read-across can be performed (e.g. common functional group(s), common precursor(s)/breakdown product(s) or common mechanism(s) of action]

It is hypothesized that the target chemical and the following chemical as source chemical should exhibit comparable toxicity profiles:
-6-(isononanoylamino)hexanoic acid, compound with 2,2`,2``-nitrilotriethanol

It is proposed to use the toxicity data of the mentioned source chemical to fulfill the data requirement for the target chemical.

The underlying scientific rationale for the use of corresponding salt as source chemical is apparent. The target chemical is a weak acid due to the terminal carboxylic acid moiety and can be neutralized/dissolved in aqueous system by reaction with base such as 2,2`,2``-nitrilotriethanol. The proposed source chemical can be formally described as carboxylate of the target chemical. As the carboxylate and carboxylic acid are inter-convertible, it is apparent that source and target chemicals are inter-convertible and should exhibit comparable toxicity profile. The base 2,2`,2``-nitrilotriethanol is a well-investigated substance and is considered to be less relevant for the proposed read-across consideration.

The proposed approach applies for all exposure routes (oral/dermal/inhalation), because both the target chemical and source chemical are expected to be bioavailable by all exposure routes: the inter-conversion between carboxylic acid and carboxylate is likely to occur prior to resorption; and the systemic release of the presumed metabolite is less dependent on exposure route.

2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
[Provide here, if relevant, additional information to that included in the Test material section of the source and target records]

Target chemical:
6-(Isononanoylamino)hexanoic acid; CAS: 71902-23-3
Source chemicals:
6-(isononanoylamino)hexanoic acid, compound with 2,2`,2``-nitrilotriethanol; CAS: 85702-79-0


The target chemical is a mono-substituent substance, the analytical purity being >99%. The source chemical is the further chemically processed products (dissolved in water with 2,2`,2``-nitrilotriethanol) of the target chemical. A toxicity difference due to different impurity profiles is not likely to occur.

3. ANALOGUE APPROACH JUSTIFICATION
[Summarise here based on available experimental data how these results verify that the read-across is justified]

Justification for the use of 6-(isononanoylamino)hexanoic acid, compound with 2,2`,2``-nitrilotriethanol as source chemical:

- The given source chemical is an ionic compound that results from the neutralization reaction of the target chemical and 2,2`,2``-nitrilotriethanol. When it is dissolved in an aqueous system or in a biological fluid, an immediate dissociation occurs to give the target chemical and the base, thereby explaining the expected comparable toxicity profile to that of target chemical.
A significant toxicity contribution of 2,2`,2``-nitrilotriethanol is not expected. 2,2`,2``-nitrilotriethanol is a well investigated substance. It is of low toxicity and the available kinetic data are demonstrative of efficient elimination mechanisms in animal models.
- In order to verify the expected toxicity comparability, the given source and the target chemicals were investigated under identical testing conditions. Both substances exhibited comparable findings after 7-day oral application to rat:
-liver and kidney enlargement
-decrease of eosinophil counts
-peroxisome proliferation in the liver
The decrease of eosinophil counts is possibly a transient effect, associated with the peroxisome proliferation stimulating effect of test compounds. No such findings were present after 28-day treatment of the source chemical.
- Comparable findings were obtained in the 28-day oral toxicity study for the given source chemical and in the above mentioned two 7-day repeated oral toxicity studies. Further special histopathological investigation revealed the alpha-2µ-globulin accumulation in male kidneys and the peroxisome proliferation in liver.
- In the available skin sensitization data the given source chemical was applied using water as vehicle. The dissociation into the target chemical and 2,2`,2``-nitrilotriethanol is expected to have occurred prior to resorption, so that the animals must have been exposed to the target chemical.

4. DATA MATRIX

Data matrix and other information see the attached read-across justification in chapter 13
Reason / purpose:
read-across source
Qualifier:
according to
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Version / remarks:
adopted on 25 June 2018
Deviations:
no
Principles of method if other than guideline:
Not applicable
GLP compliance:
yes (incl. certificate)
Limit test:
no
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source and batch No.of test material: Clariant Produkte and 18-UH-0703
- Expiration date of the batch: March 2020
- Purity test date: 24 March 2018

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Ambient (21 to 29°C)
- Stability under test conditions: The test item formulations at 1 and 100 mg/mL were stable up to 6 hours at room temperature
- Solubility and stability of the test substance in the solvent/vehicle: Clearly miscible with water at the concentration of 50 mg/mL stable upto 6 hours in ambient condition.


TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: Miscible with water to get desired concentration of 5,15 and 50 mg/mL.


FORM AS APPLIED IN THE TEST (if different from that of starting material) :Liquid

Species:
rat
Strain:
Sprague-Dawley
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: In-house bred
- Age at study initiation: 10 weeks
- Weight at study initiation: 200 to 300 grams
- Housing: Pre-mating: Maximum of three animals of same sex; Mating: 1:1 ratio; Post-mating: Males: Maximum of three animals of same sex and Females: Individual housing
- Diet (ad libitum): Altromin maintenance diet for rats and mice (manufactured by Altromin Spezialfutter GmbH & Co. KG)
- Water (ad libitum): Deep bore-well water passed through reverse osmosis unit
- Acclimation period: Minimum of five days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.7 to 22.9
- Humidity (%): 48% to 64%
- Air changes (per hr): 12 to 15 air changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours fluorescent light and 12 hours dark cycle

IN-LIFE DATES: From: 03 September 2018; To: 06 November 2018
Route of administration:
oral: gavage
Vehicle:
water
Remarks:
Not applicable
Remarks on MMAD:
Not applicable
Details on exposure:
PREPARATION OF DOSING SOLUTIONS:


VEHICLE
- Justification for use and choice of vehicle: The test item was clearly miscible with distilled water at the concentration of 50 mg/mL (highest dose concentration). Hence, distilled water was selected as a vehicle for test item formulation preparations. Distilled water is acceptable and routinely used for toxicity studies.

- Concentration in vehicle: Low dose: 5 mg/mL; Mid dose: 15 mg/mL; High dose: 50 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg body weight
- Purity: 100%
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
Dose formulation analysis for dose concentration verification was done by Analytical Chemistry department of Bioneeds India Private Limited. Sampling and analysis of formulations were performed during first week and last week of the treatment. The samples were collected in duplicates from vehicle control, low, mid and high dose concentrations.
The collected samples were transferred to Analytical Chemistry department of Bioneeds India Private Limited for dose concentration analysis. One set of aliquot of each formulation was analyzed. The second aliquot was stored as a backup purpose at established stability conditions. The second set of samples was discarded, as the analysis results of first set of samples were within the limits. Formulations were considered acceptable, as the mean results were within the range of 85 to 115% of the nominal concentration and the relative standard deviation (% RSD) is ≤10%.
Details on mating procedure:
- Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:1
- Length of cohabitation: maximum of 14 days
- After 14 days of unsuccessful pairing replacement of first male by another male with proven fertility.
- Further matings after two unsuccessful attempts: no
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy
Duration of treatment / exposure:
Gestation day 5 to 19 [15 days for each animal]
Frequency of treatment:
Once daily
Duration of test:
4 months
Dose / conc.:
0 mg/kg bw/day
Remarks:
Vehicle control
Dose / conc.:
50 mg/kg bw/day
Remarks:
Low dose
Dose / conc.:
150 mg/kg bw/day
Remarks:
Mid dose
Dose / conc.:
500 mg/kg bw/day
Remarks:
High dose
No. of animals per sex per dose:
25 mated presumed-pregnant females per dose
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: The doses of 0, 50, 150 and 500 mg/kg body weight for vehicle control, low dose, mid dose and high dose respectively were selected in consultation with the sponsor based on the results of dose range finding study for Prenatal developmental Toxicity study of 6-(isononanoylamino)hexanoic acid, compound with 2,2ꞌ,2ꞌꞌ- nitrilotriethanol (1:1) by oral gavage in Sprague Dawley Rats (Bioneeds Study No.: BIO-TX 3500).
These doses were selected as the test item when administered orally to mated and presumed-pregnant Sprague Dawley females from Gestation Day [GD] 5 to 19 and sacrificed on Gestation Day [GD] 20. The NOAEL for maternal toxicity was 150 mg/kg due to occurrence of reduced litter size and increased early resorptions at 500 mg/kg. The NOAEL for the developmental toxicity was 500 mg/kg, the high dose, due to no evidence of adverse effects on fetal developmental or incidences of external and soft tissue anomalies.

- Rationale for animal assignment (if not random): The body weight of mated females on each day of gestation day ‘0’ was recorded and arranged in the ascending order of their body weight until required number of mated females acquired for each group. These mated females were evenly distributed to all the groups based on their body weights so as to maintain comparable mean body weight for all groups and permanent identification numbers were assigned.
Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Once daily
- Cage side observations checked in table [1] were included.

DETAILED CLINICAL OBSERVATIONS: No

BODY WEIGHT: Yes
- Time schedule for examinations: Gestation Day 0, 3, 5, 8, 11, 14, 17, 19 and on 20 (day of caesarean section).

FOOD CONSUMPTION: Yes
- Food consumption for each animal determined: Yes, Gestation Day 0 to 3, 3 to 5, 5 to 8, 8 to 11, 11 to 14, 14 to 17, 17 to 19 and 19 to 20 (day of caesarean section).


POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: All sysytemic organs and tissue along with reproductiver organs
Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: The weight of thyroid along with the parathyroid was recorded post-fixation
Fetal examinations:
- External examinations: Yes: [all per litter]
- Soft tissue examinations: Yes: [half per litter]
- Skeletal examinations: Yes: [half per litter]
- Head examinations: Yes: [half per litter]
Statistics:
- Data was subjected to various statistical analysis using SPSS software version 22. All analyses and comparisons were evaluated at the 95% level of confidence (P<0.05),
- Data of non-pregnant females was not included in mean calculation and statistical analysis.

One-way ANOVA with Dunnett’s post test - Gestation body weight (g), Percent change in gestation body weight, Corrected body weight (g & %), Gravid uterus weight (g), Feed consumption (g), Fetal weights (g), Anogenital distance of all live fetuses (mm), Crown-rump length of fetuses (mm), serum T4, T3 and TSH lelvels.

Kruskal-Wallis (Non-parametric) - No. of corpora lutea, implantations, resorptions, litter size, sex ratio, implantation lossess, live/dead fetuses.

Cross Tabs Chi-square test/ Fischer's Exact Test - Pregnancy rate, No. of dams with/without live/dead fetuses, No. of dams with/without lresorptions
Indices:
Corrected Body weight (g) = (Gestation day 20 body weight - Gestation day 5 body weight) - Gravid uterus weight.

Percent of Live/Dead Fetuses = (Number of Live/Dead Fetuses / Litter Size) x 100.

Percent of Early/Late Resorptions (%) = (Number of Early/late Resorptions/ Number of Implantations) x 100.

Early Resorptions per Group (%) = (Number of Dams with Early Resorptions in the group / Total Number of Dams in the Group) x 100.

Pre-implantation Loss (%) = (Number of Corpora lutea - Number of implants) / Number of Corpora lutea x 100.

Post-implantation Loss (%) per Dam = (Number of Dams with Post-implantation loss / Total Number of Dams) x 100

Male/Female Sex Ratio = Number of live male fetuses / Number of live female fetuses.

Male/Female Fetuses (%) = (Number of live male/female fetuses / Total number of live fetuses) x 100.

Group/Litter Fetal Observation for External, Visceral and Skeletal Examinations:

Fetal incidence (%) = (Number of Fetuses with a particular observation / Total number of Fetuses in a group) x 100

Historical control data:
Not applicable
Clinical signs:
no effects observed
Description (incidence and severity):
There were no clinical signs of toxicity observed at any of the tested dose group animals (50, 150 and 500 mg/kg body weight) during the experimental period.
Dermal irritation (if dermal study):
not examined
Description (incidence and severity):
Not applicable
Mortality:
no mortality observed
Description (incidence):
There were no mortality/morbidity observed at any of the tested dose group animals (50, 150 and 500 mg/kg body weight) during the experimental period.
Body weight and weight changes:
no effects observed
Description (incidence and severity):
There were no changes noted in body weight and percent change in body weight during gestation period across all the tested dose groups (50, 150 and 500 mg/kg body weight) when compared with the vehicle control group.
Food consumption and compound intake (if feeding study):
effects observed, non-treatment-related
Description (incidence and severity):
There were no changes noted in average feed consumption during gestation period across all the tested dose groups (50, 150 and 500 mg/kg body weight) when compared with the vehicle control group. The average feed consumption (g/animal/day) across groups was comparable.
A statistically significant reduction in average feed consumption during gestation day 11 to 14 in G4 group animals was observed. This sporadic incidence is considered as incidental and unrelated to treatment with test item due to unaffected body weights during this period.
Food efficiency:
not examined
Description (incidence and severity):
Not applicable
Water consumption and compound intake (if drinking water study):
not examined
Description (incidence and severity):
Not applicable
Ophthalmological findings:
not examined
Description (incidence and severity):
Not applicable
Haematological findings:
not examined
Description (incidence and severity):
Not applicable
Clinical biochemistry findings:
not examined
Description (incidence and severity):
Not applicable
Urinalysis findings:
not examined
Description (incidence and severity):
Not applicable
Behaviour (functional findings):
not examined
Description (incidence and severity):
Not applicable
Immunological findings:
not examined
Description (incidence and severity):
Not applicable
Organ weight findings including organ / body weight ratios:
no effects observed
Description (incidence and severity):
The absolute thyroid along with parathyroid weights (g) were 0.0246, 0.0245, 0.0238 and 0.0249 and relative thyroid along with parathyroid weights (%) were 0.0062, 0.0062, 0.0061 and 0.0062 for G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no statistically significant differences in mean absolute and relative thyroid along with parathyroid weight and no treatment related changes for this parameter across the dose groups when compared to controls.
Gross pathological findings:
no effects observed
Description (incidence and severity):
There were no gross pathological changes noted in any of the dose group (50, 150 and 500 mg/kg body weight) and vehicle control group animals (0 mg/kg body weight) during conduct of the necropsy.
Neuropathological findings:
not examined
Description (incidence and severity):
Not applicable
Histopathological findings: non-neoplastic:
effects observed, non-treatment-related
Description (incidence and severity):
The histopathology of thyroid along with parathyroid was conducted for all the dose group dams (50, 150 and 500 mg/kg body weight) and vehicle control group animals (0 mg/kg body weight). There were no treatment related histopathological findings noticed in the in any of the dose group animals during conduct of the histopathological examination in the study.
Presence of ultimobranchial cysts in G1 (2 incidences), G2 (1 incidence), G3 (4 incidences) and G4 (3 incidences); ectopic thymus in G1 (1 incidence) and G4 (3 incidences) were congenital lesions and it does not have toxicological significance.
Histopathological findings: neoplastic:
not examined
Description (incidence and severity):
Not applicable
Other effects:
effects observed, non-treatment-related
Description (incidence and severity):
Serum Triiodothyronine (T3) Levels: The serum T3 levels (ng/mL) were 2.823, 2.813, 2.749 and 2.469 for G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no changes in serum T3 levels (ng/mL) across all the tested dose groups when compared with the vehicle control group. The values obtained across groups were comparable. A statistically significant reduction in serum T3 levels (ng/mL) in G4 group animals was observed. This incidence is considered as incidental and unrelated to treatment with test item due to comparable values across groups and the values obtained were within biological control range.

Serum Thyroxine (T4) Levels: The serum T4 levels (ng/mL) were 73.380, 71.373, 67.687 and 64.964 for G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no changes in serum T4 levels (ng/mL) across all the tested dose groups when compared with the vehicle control group. The values obtained across groups were comparable. A statistically significant reduction in serum T4 levels (ng/mL) in G3 and G4 group animals was observed. This incidence is considered as incidental and unrelated to treatment with test item due to comparable values across groups and the values obtained were within biological control range.


Serum Thyroid Stimulating Hormone (TSH) Levels: The serum TSH levels (µIU/mL) were 5.717, 5.539, 5.171 and 4.873 for G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no statistically significant differences in serum TSH levels and no treatment related changes for this parameter across the dose groups when compared to controls.


Details on results:
The Test item, 6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1) was administered via oral route at a dose volume of 10 mL/kg body weight to mated female rats from gestation day 5 (GD5) through gestation day 19 (GD19). The dose levels were 0 mg/kg, 50 mg/kg, 150 mg/kg and 500 mg/kg for the control (G1), low (G2), mid (G3) and high (G4) groups, respectively.

The results of the experiment support the conclusion that the NOAEL [No Observed Adverse Effect Level] for the test item, 6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1) for maternal and developmental toxicity toxicity is 500 mg/kg, the high dose, as there were no effects on maternal parameters as well as fetal parameters at all the tested dose groups.
Number of abortions:
no effects observed
Description (incidence and severity):
No abortions were noted
Pre- and post-implantation loss:
no effects observed
Description (incidence and severity):
Pre-Implantation Loss: The mean percentage pre-implantation loss was 0.00, 0.00, 0.00 and 1.92 for G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no statistically significant differences in these values and no treatment related changes for this parameter across the dose groups when compared to controls.

Post-Implantation Loss: The mean percentage of post-implantation loss was 6.89, 4.57, 9.10 and 7.75 for G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no statistically significant differences in these values and no treatment related changes for this parameter across the dose groups when compared to controls.

Overall Implantation Loss Assessment: The occurrence of implantation losses across all groups is within the historical control range for studies with this species and strain. There is no dose-related trend in the values so these losses were considered as incidental and unrelated to treatment. Dosing of test item, 6-(Isononanoylamino) hexanoic acid, compound with 2,2′,2″-nitrilotriethanol (1:1) to pregnant rats began on GD5. Implantation occurs in rats on or about GD5. For this reason any pre-implantation loss which occurred prior to the initiation of dosing cannot be treatment related.
Total litter losses by resorption:
no effects observed
Description (incidence and severity):
No such incidences noted at all the dose group dams (50, 150 and 500 mg/kg body weight) and vehicle control group animals (0 mg/kg body weight)
Early or late resorptions:
no effects observed
Description (incidence and severity):
Early Resorptions: The mean number of early resorptions per dam was 0.78, 0.54, 0.86 and 0.17 and percentage of early resorptions was 5.37, 4.31, 7.79 and 4.81 for G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no statistically significant differences observed in the number and percentage of early resorptions per dam across dose groups when compared to the vehicle control.

Late Resorptions: The mean number of late resorptions per dam was 0.22, 0.04, 0.17 and 0.33 and percentage of late resorptions was 1.52, 0.26, 1.30 and 2.94 for G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no statistically significant differences observed in the number and percentage of late resorptions per dam across dose groups when compared to the vehicle control.
Dead fetuses:
no effects observed
Description (incidence and severity):
There were no dead fetuses noted for any litter in any of the test dose group (50, 150 and 500 mg/kg body weight) or the vehicle control litters (0 mg/kg body weight).
Changes in pregnancy duration:
no effects observed
Description (incidence and severity):
All dams were sacrificed on gestation day 20
Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed
Field "Description (incidence and severity)" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.DescriptionIncidenceAndSeverityEffectsOnPregnancyDuration): All dams were sacrificed on gestation day 20
Changes in number of pregnant:
no effects observed
Description (incidence and severity):
G1 (0 mg/kg body weight): Pregnancy rate = 92.0%;
G2 (50 mg/kg body weight): Pregnancy rate = 96.0%;
G3 (150 mg/kg body weight): Pregnancy rate = 92.0%;
G4 (500 mg/kg body weight): Pregnancy rate = 96.0%.
Other effects:
no effects observed
Description (incidence and severity):
Gravid Uterus Weight and Corrected Body Weight: There were no changes noted in gravid uterus weight and body weights corrected for maternal weight across all the tested dose groups (50, 150 and 500 mg/kg body weight) when compared with the vehicle control group.
Details on maternal toxic effects:
The Test item, 6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1) was administered via oral route at a dose volume of 10 mL/kg body weight to mated female rats from gestation day 5 (GD5) through gestation day 19 (GD19). The dose levels were 0 mg/kg, 50 mg/kg, 150 mg/kg and 500 mg/kg for the control (G1), low (G2), mid (G3) and high (G4) groups, respectively.
The results of the experiment support the conclusion that the NOAEL [No Observed Adverse Effect Level] for the test item, 6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1) for maternal toxicity is 500 mg/kg, the high dose, as there were no effects on maternal parameters as well as fetal parameters at all the tested dose groups.
Key result
Dose descriptor:
NOAEL
Effect level:
>= 500 mg/kg bw/day
Based on:
test mat.
Basis for effect level:
clinical signs
mortality
body weight and weight gain
food consumption and compound intake
organ weights and organ / body weight ratios
gross pathology
histopathology: non-neoplastic
maternal abnormalities
number of abortions
pre and post implantation loss
total litter losses by resorption
effects on pregnancy duration
early or late resorptions
dead fetuses
changes in pregnancy duration
changes in number of pregnant
necropsy findings
other: Thyroid hormonal assay results [T3, T4 and TSH]
Key result
Abnormalities:
no effects observed
Localisation:
ovary
oviduct
placenta
uterus
cervix
vagina
mammary gland
amniotic fluid
umbilical cord
vitreous chamber / humor
other: thyroid
Fetal body weight changes:
effects observed, non-treatment-related
Description (incidence and severity):
For groups G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg), respectively, the male mean fetal weights were 4.35g, 4.19g, 4.07g and 4.17g; the female mean fetal weights were 3.99g, 3.99g, 3.80g and 3.89g. There were no changes in mean fetal weights across all the tested dose groups when compared with the vehicle control group. The values obtained across groups were comparable. A statistically significant reduction in mean male and female fetal weights in G3 group was observed. This incidence is considered as incidental and unrelated to treatment with test item due to comparable values across groups and also other fetal parameters are unaffected.

Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): no effects observed
Field "Description (incidence and severity)" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.DescriptionIncidenceAndSeverityFetalPupBodyWeightChanges): For groups G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg), respectively, the male mean fetal weights were 4.35g, 4.19g, 4.07g and 4.17g; the female mean fetal weights were 3.99g, 3.99g, 3.80g and 3.89g. There were no changes in mean fetal weights across all the tested dose groups when compared with the vehicle control group. The values obtained across groups were comparable. A statistically significant reduction in mean male and female fetal weights in G3 group was observed. This incidence is considered as incidental and unrelated to treatment with test item due to comparable values across groups and also other fetal parameters are unaffected.
Reduction in number of live offspring:
no effects observed
Description (incidence and severity):
The mean litter sizes, assessed as in the utero total of fetuses [live plus dead] per dam, were 12.17, 12.00, 11.48 and 11.54 for groups G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no dead fetuses within any litter in any group, therefore, the numbers of live fetuses per dam across groups were the same. There were no statistically significant differences noted across dose groups when compared to the control.
Changes in sex ratio:
no effects observed
Description (incidence and severity):
The sex ratio calculated as the mean percentage of male fetuses was 1.61, 1.41, 1.43 and 1.22 for G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no statistically significant differences in these values and no treatment related changes for this parameter across the dose groups when compared to controls.
Changes in litter size and weights:
no effects observed
Description (incidence and severity):
The mean litter sizes, assessed as in the utero total of fetuses [live plus dead] per dam, were 12.17, 12.00, 11.48 and 11.54 for groups G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg) respectively. There were no dead fetuses within any litter in any group, therefore, the numbers of live fetuses per dam across groups were the same. There were no statistically significant differences noted across dose groups when compared to the control.
Changes in postnatal survival:
not specified
Description (incidence and severity):
Not applicable, all fetuses were sacrificed on GD 20
External malformations:
effects observed, non-treatment-related
Description (incidence and severity):
A total of 280 (23), 288 (24), 238 (23) and 277 (24) fetuses (litters) with a mean of 12.17, 12.00, 11.48 and 11.54 fetuses per dam were available for gross external examination from groups G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg), respectively. No treatment related external abnormalities were noted within any group during external examination of these fetuses. However, the following variations were noted from all the group fetuses during fetal external examinations:

In G1 (vehicle control) group, haemorrhagic spot on the right fore limb in one fetus, haemorrhagic spot on tail in one fetus and haemorrhagic spot on the left hind limb in one fetus were noted.
In G2 (50 mg/kg) group, haemorrhagic spot on the fore limb bilaterally in one fetus, haemorrhagic spot on right forelimb and neck in one fetus and haemorrhagic spot on the right hind limb in one fetus were noted.
In G3 (150 mg/kg) group, haemorrhagic spot on the left forelimb in one fetus, haemorrhagic spot on left hind limb in one fetus and haemorrhagic spot on the right fore limb in one fetus were noted.
In G4 (500 mg/kg) group, haemorrhagic spot on the left forelimb in one fetus, haemorrhagic spot on right forelimb in one fetus, haemorrhagic spot on the left hind limb in one fetus and haemorrhagic spot on the hind limb bilaterally in one fetus were noted.

These findings are common for fetuses of this species and strain and cannot be considered as treatment related.
Skeletal malformations:
effects observed, non-treatment-related
Description (incidence and severity):
There were 148 (23), 150 (24), 137 (23), and 144 (24) fetuses (litters) available for skeletal examination in groups G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg), respectively. No treatment-related malformations or variations were observed during skeletal examinations of fetuses at any dose. However, the following malformations and variations were noted from all the group fetuses during fetal skeletal examinations which were not considered as treatment related:

In G1 (vehicle control) group, the malformations like, misshapen interparietal skull bones in one fetus, absence of sternum no. 5 in three fetuses and absence of proximal phalanges no. 3 and 4 bilaterally in six fetuses were noted. The variations like, poorly ossified interparietal skull bones in one fetus, poorly ossified supra occipital skull bones in two fetuses, poorly ossified sternum no. 5 in one fetus, incompletely ossified and bipartite ossified sternum no. 5 in two fetuses each, poorly ossified sternum no. 6 in two fetuses, incompletely ossified sternum no. 5 and 6 in two fetuses, discontinuous rib no. 11 unilaterally in one fetus, wavy rib no. 13 in three fetuses, dumbbell shaped centrum no. 5 and 6 of lumbar vertebrae in one fetus, extra ossification site at arch no. 4 of sacral vertebrae in two fetuses, poorly ossified centrum no. 4 of sacral vertebrae in one fetus and extra ossification site at arch no. 2 of caudal vertebrae in one fetus were noted.

In G2 (50 mg/kg) group, the malformations like, absence of sternum no. 5 in four fetuses, absence of sternum no. 6 in one fetus and absence of proximal phanges no. 3 and 4 bilaterally in seven fetuses were noted. The variations like, poorly ossified interparietal skull bones in three fetuses, poorly ossified supra occipital skull bones in two fetuses, poorly ossified sternum no. 5 in two fetuses, poorly ossified sternum no. 6 in one fetus, incompletely ossified sternum no. 6 in six fetuses, wavy rib no. 13 in two fetuses, dumbbell shaped centrum no. 5 and 6 of lumbar vertebrae in two fetuses, dumbbell shaped centrum no. 4 of lumbar vertebrae in one fetus, poorly ossified centrum no. 4 of sacral vertebrae in one fetus and extra ossification site at arch no. 2 of caudal vertebrae in two fetuses were noted.

In G3 (150 mg/kg) group, the malformations like, absence of sternum no. 5 in six fetuses and absence of proximal phalanges no. 3 and 4 bilaterally in one fetus were noted. The variations like, poorly ossified interparietal skull bones in four fetuses, poorly ossified supra occipital skull bones in two fetuses, bipartite ossified sternum no. 5 in one fetus, incompletely ossified sternum no. 6 in six fetuses, wavy rib no. 11, 12 and 13 in one fetus, extra ossification site at arch no. 4 of sacral vertebrae in four fetuses and extra ossification site at arch no. 2 of caudal vertebrae in three fetuses were noted.

In G4 (500 mg/kg) group, absence of sternum no. 5 in two fetuses, absence of sternum no. 6 in one fetus, absence of sternum no. 5 and 6 in two fetuses and absence of proximal phalanges no. 3 and 4 bilaterally in five fetuses were note. The variations like, poorly ossified supra occipital skull bones in one fetus, incompletely ossified sternum no. 6 in two fetuses each, wavy rib no. 13 in four fetuses, wavy rib no. 11, 12 and 13 in one fetus, extra ossification site at arch no. 4 of sacral vertebrae in two fetuses and extra ossification site at arch no. 2 of caudal vertebrae in five fetuses were noted.

There were multiple skeletal malformations and variations noted. These malformations and variations are correlated in that they are anatomically related but they are not uncommon findings for fetuses of this species. In general, the incidences were of a single fetus in a litter. The malformations and variations did not occur in a dose-dependent pattern, nor was the severity or the incidence of the finding increased with dose.

The skeletal malformations reflect variations in the maturation rate of the ossified tissues of rat fetuses. They are unlikely to be detectable in juvenile animals after continued growth postnatally.

These skeletal malformations did not occur in a dose-dependent pattern, nor was the severity or the incidence of the findings increased with dose.
As with the skeletal malformations, the skeletal variations reflect variations in the maturation rate of the ossified tissues of rat fetuses and they are unlikely to be detectable in juvenile animals. The skeletal variations did not occur in a dose-dependent pattern, nor was the severity or the incidence of the findings increased with dose.

Overall, the skeletal morphologic observations reflect variations in the maturation rate of the ossified tissues of rat fetuses; they did not occur in a dose-dependent pattern, nor was the severity of the anomaly increased with dose. These result support the conclusion that the findings are incidental and that the test item did not produce an adverse effect on the skeletal system during fetal development at any dose in this study.
Visceral malformations:
effects observed, non-treatment-related
Description (incidence and severity):
There were 132 (23), 138 (24), 127 (23) and 133 (24) fetuses (litters) for visceral examination in groups G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg), respectively. No treatment-related malformations or variations were observed during visceral examinations of fetuses at any dose. However, the following malformations and variations were noted from all the group fetuses during fetal visceral examinations which were not considered as treatment related:

In G1 (vehicle control) group, renal pelvis dilation unilateral (variation) in two fetuses and pale colored kidney unilaterally (variation) in one fetus were noted.

In G2 (50 mg/kg) group, cleft palate (malformation) in two fetuses and pale colored kidney unilaterally (variation) in three fetuses, dilated ventricles of brain (variation) in two fetuses and pale colored liver, kidneys and adrenals bilaterally (variation) were noted.

In G3 (150 mg/kg) group, cleft palate (malformation) in one fetus, pale colored kidneys unilaterally (variation) in three fetuses, was noted.

In G4 (500 mg/kg) group, cleft palate (malformation) in one fetus and pale colored kidney in one fetus was noted.

These observations are common findings for fetuses of this species; they did not occur in a dose-dependent pattern, nor was the severity or the incidence of the findings increased with dose. This result supports the conclusion that the findings are incidental and that the test item, 6-(Isononanoylamino) hexanoic acid, compound with 2,2′,2″-nitrilotriethanol (1:1), did not produce an adverse effect on the soft tissues during fetal development.
Other effects:
effects observed, non-treatment-related
Description (incidence and severity):
Fetal Crown rump Length: For groups G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg), respectively, the male fetal crown rump length was 39.12 mm, 38.49 mm, 37.94 mm and 38.33 mm; the female fetal crown rump length was 37.40 mm, 37.33 mm, 36.45 mm and 36.80 mm. There were no statistically significant differences in fetal crown rump length and no treatment related changes for this parameter across the dose groups when compared to controls.

Fetal Ano-genital Distance Ratio: For groups G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg), respectively, the mean male ano-genital distance was 2.55 mm, 2.55 mm, 2.54 mm and 2.60 mm; the mean female ano-genital distance was 1.39 mm, 1.37 mm, 1.28 mm and 1.36 mm. There were no changes in mean ano-genital distance across all the tested dose groups when compared with the vehicle control group. The values obtained across groups were comparable. A statistically significant reduction in mean female ano-genital distance in G3 group was observed. This incidence is considered as incidental and unrelated to treatment with test item due to comparable values across groups and also other fetal parameters are unaffected.
Details on embryotoxic / teratogenic effects:
The Test item, 6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1) was administered via oral route at a dose volume of 10 mL/kg body weight to mated female rats from gestation day 5 (GD5) through gestation day 19 (GD19). The dose levels were 0 mg/kg, 50 mg/kg, 150 mg/kg and 500 mg/kg for the control (G1), low (G2), mid (G3) and high (G4) groups, respectively. The results of the experiment support the conclusion that the NOAEL [No Observed Adverse Effect Level] for the test item, 6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1) for fetal toxicity is 500 mg/kg, the high dose, as there were no effects on fetal parameters at all the tested dose groups.
Key result
Dose descriptor:
NOAEL
Effect level:
>= 500 mg/kg bw/day
Based on:
test mat.
Sex:
male/female
Basis for effect level:
reduction in number of live offspring
changes in sex ratio
fetal/pup body weight changes
changes in litter size and weights
external malformations
skeletal malformations
visceral malformations
other: Fetal Crown rump Length and Ano-genital Distance Ratio
Key result
Abnormalities:
no effects observed
Localisation:
external: cranium
external: ear
external: eye
external: face
external: limb
external: paw
external: tail
external: trunk
external: anogenital distance
external: anus
external: genital tubercle
external: large intestine
external: thorax
external: umbilicus
external: pelvic region
skeletal: skull
skeletal: skull, fontanelles
skeletal: skull sutures
skeletal: clavicle
skeletal: scapule
skeletal: forelimb
skeletal: sternum
skeletal: rib
skeletal: supernumerary rib
skeletal: vertebra
skeletal: pelvic girdle
skeletal: hindlimb
visceral/soft tissue: integumentary
visceral/soft tissue: gastrointestinal tract
visceral/soft tissue: hepatobiliary
visceral/soft tissue: urinary
visceral/soft tissue: cardiovascular
visceral/soft tissue: heamatopoietic
visceral/soft tissue: immune system
visceral/soft tissue: musculoskeletal system
visceral/soft tissue: nervous system
visceral/soft tissue: central nervous system
visceral/soft tissue: peripheral nervous system
visceral/soft tissue: somatic nervous system
visceral/soft tissue: autonomic nervous system
visceral/soft tissue: endocrine system
visceral/soft tissue: respiratory system
visceral/soft tissue: male reproductive system
visceral/soft tissue: female reproductive system
visceral/soft tissue: eye
visceral/soft tissue: ear
Key result
Developmental effects observed:
no
Lowest effective dose / conc.:
500 mg/kg bw/day
Treatment related:
no

TABLE 1.        SUMMARY OF CLINICAL SIGNS OF TOXICITY AND MORTALITY RECORD

Group & Dose (mg/kg body weight)

No. of Animals

Clinical Signs of Toxicity during Gestation Period

Mortality
(No. of Mortality /
No. of Animals dosed)

G1 & 0

25

N

0/25

G2 & 50

25

N

0/25

G3 & 150

25

N

0/25

G4 & 500

25

N

0/25

N: Normal

TABLE 2.        SUMMARY OF GESTATION BODY WEIGHT (g)

                

Group & Dose

(mg/kg body weight)

Body Weight (g) on Gestation Day

0

3

5

8

11

14

17

19

20

G1 & 0

Mean

281.51

292.45

299.22

307.27

321.95

333.84

359.85

388.29

404.13

±SD

28.61

31.10

32.54

32.40

32.74

32.11

32.25

36.80

37.83

n

23

23

23

23

23

23

23

23

23

G2 & 50

Mean

275.83

288.58

293.92

302.10

317.06

331.46

355.73

381.64

396.79

±SD

15.98

16.46

18.25

18.20

19.05

21.41

24.04

28.37

30.81

n

24

24

24

24

24

24

24

24

24

G3 & 150

Mean

279.02

290.25

297.51

305.10

320.59

332.47

355.97

380.93

394.24

±SD

17.56

18.45

18.64

17.80

20.19

20.45

23.81

28.39

29.76

n

23

23

23

23

23

23

23

23

23

G4 & 500

Mean

287.16

300.56

307.45

313.68

324.94

337.97

362.02

385.91

402.84

±SD

21.25

22.11

23.39

23.99

25.25

26.39

31.26

37.97

39.37

n

24

24

24

24

24

24

24

24

24

SD: Standard Deviation; n: number of animals

 

TABLE 3.        SUMMARY OF PERCENT CHANGE IN GESTATION BODY WEIGHT (%) RECORD

                                                                                                            

Group & Dose (mg/kg body weight)

Percent Change in Body Weight (%) during Gestation Day

0-3

3-5

5-8

8-11

11-14

14-17

17-19

19-20

5-20

G1 & 0

Mean

3.86

2.30

2.73

4.84

3.76

7.88

7.90

4.10

35.45

±SD

2.35

1.48

1.41

2.07

1.76

2.90

3.50

1.52

7.79

n

23

23

23

23

23

23

23

23

23

G2 & 50

Mean

4.65

1.83

2.80

4.97

4.53

7.33

7.26

3.96

35.06

±SD

2.13

1.09

1.42

1.96

1.91

2.59

2.27

1.49

7.41

n

24

24

24

24

24

24

24

24

24

G3 & 150

Mean

4.04

2.52

2.58

5.10

3.73

7.06

6.98

3.50

32.59

±SD

2.02

1.31

1.32

3.40

1.69

2.28

2.37

1.65

7.09

n

23

23

23

23

23

23

23

23

23

G4 & 500

Mean

4.69

2.28

2.03

3.59

4.02

7.07

6.52

4.40

30.92

±SD

1.87

1.23

1.05

1.55

1.43

2.55

2.93

1.73

6.31

n

24

24

24

24

24

24

24

24

24

SD: Standard Deviation; n: No. of animals

TABLE 4.        SUMMARY OF GRAVID UTERUS WEIGHT AND CORRECTED BODY WEIGHT RECORD

                                                                                                                                     

Group & Dose

(mg/kg body weight)

Gravid Uterus Weight (g)

Body Weight Change (g) from GD 5 to GD 20

Corrected Body weight (g)

Corrected Body weight (%)

G1 & 0

Mean

76.30

104.91

28.62

9.79

±SD

17.14

19.58

11.71

4.32

n

23

23

23

23

G2 & 50

Mean

73.22

102.87

29.66

10.13

±SD

18.45

21.96

10.63

3.73

n

24

24

24

24

G3 & 150

Mean

67.77

96.73

28.95

9.78

±SD

12.36

21.07

11.74

3.94

n

23

23

23

23

G4 & 500

Mean

70.39

95.39

25.00

8.18

±SD

22.86

21.93

7.68

2.61

n

24

24

24

24

SD: Standard Deviation; n: No. of animals

TABLE 5.        SUMMARY OF AVERAGE FFED CONSUMPTION (g/animal/day)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                Refer

Group & Dose (mg/kg body weight)

Feed Consumption on Gestation Day (g/animal/day)

0-3

3-5

5-8

8-11

11-14

14-17

17-19

19-20

G1 & 0

Mean

17.14

22.10

19.77

21.26

23.72

25.54

27.55

26.36

±SD

2.60

2.85

2.16

2.27

2.61

2.29

2.74

3.62

n

23

23

23

23

23

23

23

23

G2 & 50

Mean

17.39

21.17

18.98

20.91

22.78

24.82

27.80

26.91

±SD

2.33

2.70

2.32

1.83

2.24

2.70

3.16

3.22

n

24

24

24

24

24

24

24

24

G3 & 150

Mean

15.96

21.93

19.03

20.65

22.45

24.69

26.23

26.79

±SD

2.38

4.70

2.38

1.89

2.53

2.35

2.38

3.66

n

23

23

23

23

23

23

23

23

G4 & 500

Mean

17.28

21.23

18.88

19.92

21.49*

23.94

26.31

26.42

±SD

2.96

3.09

2.08

2.05

2.20

2.08

2.52

3.49

n

24

24

24

24

24

24

24

24

SD: Standard Deviation; n: No. of animals

*. The mean difference is significant at the 0.05 level.

TABLE 6.        SUMMARY OF UTERI OBSERVATION RECORD

           

Group & Dose

(mg/kg body weight)

No. of

Corporalutea

No. of Implantations

Litter size

No. of Live Fetuses

No. of Male Live Fetuses

No. of Female Live Fetuses

No. of Dead Fetuses

No. of Early Resorptions

No. of Late Resorptions

G1 & 0

Mean

13.17

13.17

12.17

12.17

7.09

5.09

0.00

0.78

0.22

±SD

2.95

2.95

2.72

2.72

2.31

1.81

0.00

1.04

0.42

n

23

23

23

23

23

23

23

23

23

G2 & 50

Mean

12.58

12.58

12.00

12.00

6.13

5.88

0.00

0.54

0.04

±SD

3.23

3.23

3.20

3.20

2.07

2.58

0.00

0.72

0.20

n

24

24

24

24

24

24

24

24

24

G3 & 150

Mean

12.61

12.61

11.48

11.48

5.96

5.52

0.00

0.96

0.17

±SD

1.80

1.80

2.09

2.09

2.23

2.00

0.00

1.02

0.49

n

23

23

23

23

23

23

23

23

23

G4 & 500

Mean

12.67

12.42

11.54

11.54

5.71

5.83

0.00

0.17

0.33

±SD

3.71

3.89

3.99

3.99

2.27

2.68

0.00

0.78

0.56

n

24

24

24

24

24

24

24

24

24

 SD: Standard Deviation; n: No. of animals

TABLE 7.        SUMMARY OF MATERNAL DATA RECORD

Group & Dose (mg/kg body weight)

Pre-Implantation Loss (%)

Post-Implantation Loss (%)

Percent of Dead Fetus

Percent of Early Resorptions

Percent of Late Resorptions

Male / Female Sex ratio

Male Fetuses (%)

Female Fetuses (%)

Percent of Live Fetuses

G1 & 0

Mean

0.00

6.89

0.00

5.37

1.52

1.61

57.70

42.30

100.00

±SD

0.00

8.65

0.00

7.13

2.97

0.86

13.15

13.15

0.00

n

23

23

23

23

23

23

23

23

23

G2 & 50

Mean

0.00

4.57

0.00

4.31

0.26

1.41

50.81

49.19

100.00

±SD

0.00

5.58

0.00

5.64

1.28

1.27

18.46

18.46

0.00

n

24

24

24

24

24

24

24

24

24

G3 & 150

Mean

0.00

9.10

0.00

7.79

1.30

1.43

51.77

48.23

100.00

±SD

0.00

8.79

0.00

8.18

3.86

1.33

15.21

15.21

0.00

n

23

23

23

23

23

23

23

23

23

G4 & 500

Mean

1.92

7.75

0.00

4.81

2.94

1.22

54.00

51.56

100.00

±SD

9.42

11.72

0.00

8.25

5.04

0.70

18.22

21.06

0.00

n

24

24

24

24

24

24

24

24

24

G: Group; SD: Standard Deviation; n: Number of dams

TABLE 8.        SUMMARY OF ABSOLUTE THYROID ALONG WITH PARATHYROID WEIGHT (g) RECORD

Group & Dose

(mg/kg body weight)

Thyroid along with parathyroid#

G1 & 0

Mean

0.0246

±SD

0.0045

n

23

G2 & 50

Mean

0.0245

±SD

0.0041

n

24

G3 & 150

Mean

0.0238

±SD

0.0022

n

23

G4 & 500

Mean

0.0249

±SD

0.0036

n

24

SD: Standard Deviation; n: Number of animals; #: Weighed post fixation

TABLE 9.        SUMMARY OF TERMINAL BODY WEIGHT (g) AND ORGAN WEIGHT (%) RELATIVE TO TERMINAL BODY WEIGHT RECORD

Refer Appendix 9

Group & Dose

(mg/kg body weight)

Terminal Body Weight (g)

Thyroid along with parathyroid

G1 & 0

Mean

404.13

0.0062

±SD

37.83

0.0014

n

23

23

G2 & 50

Mean

396.79

0.0062

±SD

30.81

0.0011

n

24

24

G3 & 150

Mean

394.24

0.0061

±SD

29.76

0.0007

n

23

23

G4 & 500

Mean

402.84

0.0062

±SD

39.37

0.0011

n

24

24

 SD: Standard Deviation; n: Number of animals

TABLE 10.        SUMMARY OF SERUM TRIIODOTHYRONINE (T3) LEVELS (ng/mL) RECORD

Group & Dose

(mg/kg body weight)

Serum T3 Levels (ng/mL)

G1 & 0

Mean

2.823

±SD

0.203

n

23

G2 & 50

Mean

2.813

±SD

0.204

n

24

G3 &150

Mean

2.749

±SD

0.236

n

23

G4 & 500

Mean

2.469*

±SD

0.254

n

24

SD: Standard Deviation; n: Number of animals;*. The mean difference is significant at the 0.05 level

TABLE 11.        SUMMARY OF SERUM THYROXINE (T4) LEVELS (ng/mL) RECORD

Refer Appendix 11

Group & Dose

(mg/kg body weight)

 

Serum T4 Levels (ng/mL)

G1 & 0

Mean

73.380

±SD

6.397

n

23

G2 & 50

Mean

71.373

±SD

7.325

n

24

G3 &150

Mean

67.687*

±SD

5.189

n

23

G4 & 500

Mean

64.964*

±SD

4.666

n

24

G: Group; SD: Standard Deviation; n: Number of dams;*. The mean difference is significant at the 0.05 level

TABLE 12.        SUMMARY OF SERUM THYROID STIMULATING HORMONE (TSH) LEVELS (µIU/mL) RECORD

Refer Appendix 12

Group & Dose

(mg/kg body weight)

Serum TSH Levels (µIU/mL)

G1 & 0

Mean

5.717

±SD

6.676

n

23

G2 & 50

Mean

5.539

±SD

3.888

n

24

G3 & 150

Mean

5.171

±SD

3.487

n

23

G4 & 500

Mean

4.873

±SD

2.785

n

24

SD: Standard Deviation; n: Number of animals

TABLE 13.        SUMMARY OF FETAL WEIGHT (g) RECORD

Refer Appendix 13

Group & Dose

(mg/kg body Weight)

Fetus Weight

Mean Male

Fetal Weight (g)

Mean Female Fetal Weight (g)

G1 & 0

Mean

4.35

3.99

±SD

0.23

0.27

n

23

23

G2 & 50

Mean

4.19

3.99

±SD

0.28

0.29

n

23

24

G3 & 150

Mean

4.07*

3.80*

±SD

0.35

0.32

n

23

23

G4 & 500

Mean

4.17

3.89

±SD

0.19

0.24

n

24

24

SD: Standard Deviation; n: Number of animals

*: The mean difference is significant at the 0.05 level

TABLE 14.        SUMMARY OF CROWN RUMP LENGTH (mm) RECORD                                                                                                                                         

                                                                                                          Refer Appendix 14

Group & Dose

(mg/kg body weight)

CR Length (mm)

Male

Female

G1 & 0

Mean

39.12

37.40

±SD

2.05

2.66

n

23

23

G2 & 50

Mean

38.49

37.33

±SD

1.58

2.56

n

23

24

G3 & 150

Mean

37.94

36.45

±SD

2.67

2.82

n

23

23

G4 & 500

Mean

38.33

36.80

±SD

2.44

2.85

n

24

24

SD: Standard Deviation; n: Number of animals

TABLE 15.        SUMMARY OF ANOGENITAL DISTANCE (AGD) RATIO RECORD

Refer Appendix 15

Group & Dose

(mg/kg body weight)

AGD Ratio

Mean Male AGD Ratio

Mean Female AGD Ratio

G1 & 0

Mean

2.55

1.39

±SD

0.15

0.19

n

23

23

G2 & 50

Mean

2.55

1.37

±SD

0.10

0.10

n

23

24

G3 & 150

Mean

2.54

1.28*

±SD

0.13

0.14

n

23

23

G4 & 500

Mean

2.60

1.36

±SD

0.12

0.11

n

24

24

SD: Standard Deviation; n: Number of animals;*:The mean difference is significant at the 0.05 level

TABLE 16.        SUMMARY RECORD OF FETAL EXTERNAL EXAMINATION

Refer Appendix16

Parameters

Group

G1

G2

G3

G4

Dose
(mg/kg body weight)

0

50

150

500

Number of Dams

23

24

23

24

Number of fetuses for External Examination

280

288

264

277

Number of fetuses observed with No Abnormality Detected

277

285

261

273

Number of fetuses observed with Malformations

0

0

0

0

Number of fetuses observed with Variations

3

3*

3

4

VARIATIONS

HAEMORRHAGIC SPOT ON

Right Fore Limb (Unilateral)

No.

1 (1)

1 (1)

1 (1)

1 (1)

%

0.36

0.35

0.38

0.36

Left Fore Limb (Unilateral)

No.

0 (0)

0 (0)

1 (1)

1 (1)

%

0.00

0.00

0.38

0.36

Fore Limb (Bilateral)

No.

0 (0)

1 (1)

0 (0)

0 (0)

%

0.00

0.35

0.00

0.00

Right Hind Limb (Unilateral)

No.

0 (0)

1 (1)

0 (0)

0 (0)

%

0.00

0.35

0.00

0.00

Left Hind Limb (Unilateral)

No.

1 (1)

0 (0)

1 (1)

1 (1)

%

0.36

0.00

0.38

0.36

Hind Limb (Bilateral)

No.

0 (0)

0 (0)

0 (0)

1 (1)

%

0.00

0.00

0.00

0.36

Neck

No.

0 (0)

1 (1)

0 (0)

0 (0)

%

0.00

0.35

0.00

0.00

Tail

No.

1 (1)

0 (0)

0 (0)

0 (0)

%

0.36

0.00

0.00

0.00

Number of dams in parentheses

*: One fetus observed with haemorrhagic spot onbothright fore limb & neck region.

TABLE 17.        SUMMARY RECORD OF FETAL VISCERAL EXAMINATION

Parameters

Group

G1

G2

G3

G4

Dose

(mg/kg body weight)

0

50

150

500

Number of Dams

23

24

23

24

Number of fetuses for visceral examination

132

138

127

133

Number of fetuses observed with No Abnormality Detected

129

131

123

131

Number of fetuses observed with Malformations

0

2

1

1

Number of fetuses observed with Variations

3

6

3

1

MALFORMATIONS

 

Head - Cleft palate (malformed)

No.

0 (0)

2 (2)

1 (1)

1 (1)

%

0.00

1.45

0.79

0.75

VARIATIONS

Kidney - Renal pelvis Dilation - Unilateral (right)

No.

2 (2)

0 (0)

0 (0)

0 (0)

%

1.5

0.00

0.00

0.00

Kidney - Pale colored - Unilateral (right)

No.

1 (1)

3 (3)

2 (2)

0 (0)

%

0.76

2.17

1.57

0.00

Brain - Ventricles dilated

No.

0 (0)

2 (2)

0 (0)

0 (0)

%

0.00

1.45

0.00

0.00

Liver, Adrenals, Kidneys:

Pale colored

No.

0 (0)

1 (1)

0 (0)

0 (0)

%

0.00

0.72

0.00

0.00

Kidney: Pale colored - Unilateral (left)

No.

0 (0)

0 (0)

1 (1)

1 (1)

%

0.00

0.00

0.79

0.75

Number of dams in parentheses

 

 

 

No. of fetuses with abnormality

% of Abnormality

:

------------------------------------------ X 100

 

 

 Total No. of fetuses examined

TABLE 18.        SUMMARY OF SKELETAL EXAMINATION OF FETUSES

Parameters

Group

G1

G2

G3

G4

Dose (mg/kg body weight)

0

50

150

500

Number of Dams

23

24

23

24

Number of fetuses for skeletal examination

148

150

137

144

Number of fetuses observed with No Abnormality Detected

117

116

109

119

Number of fetuses observed with Malformations

10

12

7

10

Number of fetuses observed with Variations

21

22

21

15

MALFORMATIONS

SKULL

Skull - Misshapen

No.

1 (1)

0 (0)

0 (0)

0 (0)

%

0.68

0.0

0.0

0.0

STERNUM

Sternum No. 5 - Absent

No.

3 (3)

4 (4)

6 (6)

2 (2)

%

2.01

2.67

4.38

1.39

Sternum No. 6 - Absent

No.

0 (0)

1 (1)

0 (0)

1 (1)

%

0.00

0.67

0.00

0.72

Sternum No. 5 and 6 - Absent

No.

0 (0)

0 (0)

0 (0)

2 (2)

%

0.00

0.00

0.00

1.39

FORE LIMB

Proximal phalanx No. 3 and 4 - Absent (Bilateral)

No.

6 (6)

7 (7)

1 (1)

5 (5)

%

4.05

4.67

0.73

3.47

Number of dams in parentheses

                                                                           

 

 

No. of fetuses with abnormality

% of Abnormality

:

------------------------------------------ X 100

 

 

 Total No. of fetuses examined

TABLE 18 (Contd..,). SUMMARY OF SKELETAL EXAMINATION OF FETUSES


Parameters

Group

G1

G2

G3

G4

Dose (mg/kg body weight)

0

50

150

500

Number of Dams

23

24

23

24

Number of fetuses for skeletal examination

148

150

137

144

Number of fetuses observed with No Abnormality Detected

117

116

109

119

Number of fetuses observed with Malformations

10

12

7

10

Number of fetuses observed with Variations

21

22

21

15

VARIATIONS

SKULL

Intra parietal bones - Poor Ossification

No.

1 (1)

3 (3)

4 (4)

0 (0)

%

0.68

2.00

2.92

0.00

Supraoccipital bones - Poor Ossification

No.

2 (2)

2 (2)

2 (2)

1 (1)

%

1.35

1.33

1.46

0.69

STERNUM

Sternum No. 5 - Poor Ossification

No.

1 (1)

2 (2)

0 (0)

0 (0)

%

0.68

1.33

0.00

0.00

Sternum No. 5 - Incomplete Ossification

No.

2 (2)

0 (0)

0 (0)

0 (0)

%

1.35

0.00

0.00

0.00

Sternum No. 5 - Bipartite Ossification

No.

2 (2)

0 (0)

1 (1)

0 (0)

%

1.35

0.00

0.73

0.00

Sternum No. 6 - Poor Ossification

No.

2 (2)

1 (1)

0 (0)

0 (0)

%

1.35

0.67

0.00

0.00

Sternum No. 6 - Incomplete Ossification

No.

0 (0)

6 (6)

6 (6)

2 (2)

%

0.00

4.00

4.38

1.39

Sternum No. 5 and 6 - Incomplete Ossification

No.

2 (2)

0 (0)

0 (0)

0 (0)

%

1.35

0.00

0.00

0.00

 Number of dams in parentheses

 

 

 

No. of fetuses with abnormality

% of Abnormality

:

------------------------------------------ X 100

 

 

 Total No. of fetuses examined

TABLE 18 (Contd..,). SUMMARY OF SKELETAL EXAMINATION OF FETUSES

Refer Appendix 18


Parameters

Group

G1

G2

G3

G4

Dose (mg/kg body weight)

0

50

150

500

Number of Dams

23

24

23

24

Number of fetuses for skeletal examination

148

150

137

144

Number of fetuses observed with No Abnormality Detected

117

116

109

119

Number of fetuses observed with Malformations

10

12

7

10

Number of fetuses observed with Variations

21

22

21

15

VARIATIONS

RIBS

Rib No. 1 - Discontinuous (unilateral)

No.

1 (1)

0 (0)

0 (0)

0 (0)

%

0.68

0.00

0.00

0.00

Rib No. 13 - Wavy

No.

3 (3)

2 (2)

0 (0)

4 (4)

%

2.03

1.33

0.00

2.78

Rib No. 11,12 and 13 - Wavy

No.

0 (0)

0 (0)

1 (1)

1 (1)

%

0.00

0.00

0.73

0.69

LUMBAR VERTEBRAE

Centrum No. 5 and 6 - Dumbbell shaped

No.

1 (1)

2 (2)

0 (0)

0 (0)

%

0.68

1.33

0.00

0.00

Centrum No. 4 -

Dumbbell shaped

No.

0 (0)

1 (1)

0 (0)

0 (0)

%

0.00

0.67

0.00

0.00

SACRAL VERTEBRAE

Extra Ossification Site -

Arch No.4

No.

2 (2)

0 (0)

4 (4)

2 (2)

%

1.35

0.00

2.92

1.39

Centrum no. 4 -

Poor Ossification

No.

1 (1)

1 (1)

0 (0)

0 (0)

%

0.68

0.67

0.00

0.00

CAUDAL VERTEBRAE

Extra Ossification Site -

 Arch No.2

No.

1 (1)

2 (2)

3 (3)

5 (5)

%

0.68

1.33

2.19

3.47

 Number of dams in parentheses

 

 

 

No. of fetuses with abnormality

% of Abnormality

:

------------------------------------------ X 100

 

 

 Total No. of fetuses examined

Conclusions:
The development toxicity of the registered substance is assessed based on analougue approach using 6-(Isononanoylamino) hexanoic acid, compound with 2,2′,2″-nitrilotriethanol (1:1) as source substance.
The Test item, 6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1) was administered via oral route at a dose volume of 10 mL/kg body weight to mated female rats from gestation day 5 (GD5) through gestation day 19 (GD19). The dose levels were 0 mg/kg, 50 mg/kg, 150 mg/kg and 500 mg/kg for the control (G1), low (G2), mid (G3) and high (G4) groups, respectively.
The results of the experiment support the conclusion that the NOAEL [No Observed Adverse Effect Level] for the test item, 6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1) for maternal and developmental toxicity toxicity is 500 mg/kg, the high dose, as there were no effects on maternal parameters as well as fetal parameters at all the tested dose groups.

Based on the analogue approach, the NOAEL of the subimission substance is also considered to be 500 mg/kg bw. No effects regarding developental toxicity are expected.
Executive summary:

The development toxicity of the registered substance is assessed based on analougue approach using 6-(Isononanoylamino) hexanoic acid, compound with 2,2′,2″-nitrilotriethanol (1:1) as source substance.

The test item,6-(Isononanoylamino) hexanoic acid, compound with  2, 2′, 2″-nitrilotriethanol (1:1), was administeredby the oral routeat 10 mL/kg body weight to mated and presumed-pregnant females from Gestation Day [GD] 5 to 19. For dams the end points of assessment were maternal death, maternal body weight and clinical signs of maternal toxicity. In the fetuses the end points of assessment were fetal death, structural variations and malformations or altered growth.

A total of 100 mated female Sprague Dawley rats were allocated to four groups. Each group consisted of 25 matedpresumed-pregnant female Sprague Dawley rats (Dams).6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1)was administered by the oral route in graduated doses at three dose levels:

Group G1: 0 mg/kg (Vehicle Control)

Group G2: 50 mg/kg (Low Dose)

Group G3: 150 mg/kg (Mid Dose)

Group G4: 500 mg/kg (High Dose)

All the animals were observed for clinical signs of toxicity once daily, mortalities twice daily during the experimental period, the body weight and feed consumption were recorded on 0, 3, 5, 8, 11, 14, 17, 19 and on 20(day of caesarean section). On the day of caesarean section, all the dams were observed for gravid uterus weight, uteri observations (no. of corpora lutea, no. of implantations, no. of resorptions and no of live and foetuses). The sex ratio, pre/post implantation loss per dam, percentage of male and female foetuses was calculated based on the uteri observations. The weight of thyroid along with the parathyroid was recorded post-fixation for all the group animals.

All the animals were euthanized on gestation Day 20 by exposing to CO2and subjected to detailed gross pathological examination. The histopathology of thyroid along with parathyroid conducted for all the tested dose group animals.

A total number of 24, 23, 24 and 23 mated females were confirmed pregnant across groups yielding pregnancy rates of 96%, 92%, 96% and 92% at the time of caesarean section for the G1 (0 mg/kg), G2 (50 mg/kg), G3 (150 mg/kg) and G4 (500 mg/kg), respectively.

No clinical signs of toxicity and no mortalitieswere noted during the experimental period at all the tested dose group animals.No treatment related effects were observed on gestational body weight, body weight gain and corrected body weight across the dose groups when compared with controls. There were no treatment related differences in feed consumption across the dose groups during gestation period.

No treatment related changes were noted ingravid uterus weight, uteri observations (no. of corpora lutea, no. of implantations, no. of resorptions and no of live and foetuses), sex ratio, pre/post implantation loss per dam, percentage of male and female foetuses and weight of thyroid along with the parathyroid wat all the tested dose groups.

No gross pathological findings were reported in all the tested dose groups during conductance of the necropsy.

The histopathology of thyroid along with parathyroid conducted for all the dose group dams did not reveal any treatment related histopathological findings during conduct of the histopathological examination. Presence of ultimobranchial cysts in G1 (2 incidences), G2 (1 incidence), G3 (4 incidences) and G4 (3 incidences); ectopic thymus in G1 (1 incidence) and G4 (3 incidences) were congenital lesions and it does not have toxicological significance.

For the maternal toxicity assessment, the results of the experiment support that there were no treatment related effects on maternal body weight, feed consumption, forthe parameters which assess gestational integrity end points, e.g.mean gravid uterus weight, number of corpora lutea, number of implantations, litter size, number of live fetuses, number of dead fetuses,mean number of early resorptions per dam and percentage of implantation losses per damacross all the groups.

The gravid uterus was collected by hysterectomy and fetuses were removed by caesarean section. The fetuses were observed for fetal weights, crown rump length, ano-genital distance, observation of reproductive tract, comparison of external fetal sex with internal gonads. Examination of fetuses forexternal, soft tissue, and skeletal anomalieswas performed.

Notreatment relatedeffects on fetal weight, crown-rump length, fetal ano-genital distance ratio and comparison of external fetal sex with internal gonads were noted at all the tested dose groups.

No treatment related gross external abnormalities were noted within any group after external examination of fetuses. The noted findings of haemorrhagic spots on the are common findings for fetuses of this species and strain.

No treatment-related abnormalities were observed during visceral examinations of fetuses at any dose. The noted findings of renal pelvic dilation, pale colored kidneys, and pale colored adrenals are anatomical variations which are common findings for fetuses of this species and strain. The observations were not dose dependent, nor were the severity of the anomaly increased with dose. This result supports the conclusion that the findings are incidental and that the test item did not produce an adverse effect on the soft tissues during fetal development.

No treatment-related abnormalities were observed during skeletal examinations of fetuses at any dose. Split thoracic/lumbar vertebral centrum; absence of proximal phalanges no. 3 and 4; absence of sternum no. 5 and 6 were recorded as malformations. Poorly ossified sternum no. 5 and 6, sacral vertebrae centrum, dumbbell shaped thoracic/lumbar/sacral vertebrae, extra ossification site on caudal vertebrae and wavy ribs were recorded as variations. The noted anomalies are common findings for fetuses of this species and strain. They did not occur in a dose-dependent pattern, nor was the severity of the anomalies increased with dose. This result supports the conclusion that the findings are incidental and that the test item, did not produce an adverse effect on the skeletal tissues during fetal development. 

For the developmental toxicity assessment, the results of the experiment support that there were notreatment relatedeffects on the parameters which assess fetal development, i.e. fetal weight, crown-rump length, fetal ano-genital distance ratio and incidences of external, soft tissue or skeletal anomalies.

The results of the experiment support the conclusion that the NOAEL [No Observed Adverse Effect Level] for the test item,6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1)for maternal and developmental toxicity was 500 mg/kg, the high dose, as there were no effects on maternal parameters as well as fetal parameters at all the tested dose group

Based on the analogue approach, the NOAEL of the subimission substance is also considered to be 500 mg/kg bw. No effects regarding developental toxicity are expected.

Effect on developmental toxicity: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
500 mg/kg bw/day
Study duration:
subacute
Species:
rat
Quality of whole database:
This OECD 414 study is reliable (Klimisch 1). The quality of the database is considered sufficient.
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available
Additional information

The development toxicity of the registered substance is assessed based on analougue approach using6-(Isononanoylamino) hexanoic acid, compound with 2,2′,2″-nitrilotriethanol (1:1) as source substance.

The test item,6-(Isononanoylamino) hexanoic acid, compound with  2, 2′, 2″-nitrilotriethanol (1:1), was administeredby the oral routeat 10 mL/kg body weight to mated and presumed-pregnant females from Gestation Day [GD] 5 to 19. For dams the end points of assessment were maternal death, maternal body weight and clinical signs of maternal toxicity. In the fetuses the end points of assessment were fetal death, structural variations and malformations or altered growth.

A total of 100 mated female Sprague Dawley rats were allocated to four groups. Each group consisted of 25 matedpresumed-pregnant female Sprague Dawley rats (Dams).6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1)was administered by the oral route in graduated doses at three dose levels:

Group G1: 0 mg/kg (Vehicle Control)

Group G2: 50 mg/kg (Low Dose)

Group G3: 150 mg/kg (Mid Dose)

Group G4: 500 mg/kg (High Dose)

All the animals were observed for clinical signs of toxicity once daily, mortalities twice daily during the experimental period, the body weight and feed consumption were recorded on 0, 3, 5, 8, 11, 14, 17, 19 and on 20(day of caesarean section). On the day of caesarean section, all the dams were observed for gravid uterus weight, uteri observations (no. of corpora lutea, no. of implantations, no. of resorptions and no of live and foetuses). The sex ratio, pre/post implantation loss per dam, percentage of male and female foetuses was calculated based on the uteri observations. The weight of thyroid along with the parathyroid was recorded post-fixation for all the group animals.

No clinical signs of toxicity and no mortalitieswere noted during the experimental period at all the tested dose group animals.No treatment related effects were observed on gestational body weight, body weight gain and corrected body weight across the dose groups when compared with controls. There were no treatment related differences in feed consumption across the dose groups during gestation period.

No treatment related changes were noted ingravid uterus weight, uteri observations (no. of corpora lutea, no. of implantations, no. of resorptions and no of live and foetuses), sex ratio, pre/post implantation loss per dam, percentage of male and female foetuses and weight of thyroid along with the parathyroid wat all the tested dose groups.

No gross pathological findings were reported in all the tested dose groups during conductance of the necropsy.

The histopathology of thyroid along with parathyroid conducted for all the dose group dams did not reveal any treatment related histopathological findings during conduct of the histopathological examination. Presence of ultimobranchial cysts in G1 (2 incidences), G2 (1 incidence), G3 (4 incidences) and G4 (3 incidences); ectopic thymus in G1 (1 incidence) and G4 (3 incidences) were congenital lesions and it does not have toxicological significance.

For the maternal toxicity assessment, the results of the experiment support that there were no treatment related effects on maternal body weight, feed consumption, forthe parameters which assess gestational integrity end points, e.g.mean gravid uterus weight, number of corpora lutea, number of implantations, litter size, number of live fetuses, number of dead fetuses,mean number of early resorptions per dam and percentage of implantation losses per damacross all the groups.

The gravid uterus was collected by hysterectomy and fetuses were removed by caesarean section. The fetuses were observed for fetal weights, crown rump length, ano-genital distance, observation of reproductive tract, comparison of external fetal sex with internal gonads. Examination of fetuses forexternal, soft tissue, and skeletal anomalieswas performed.

Notreatment relatedeffects on fetal weight, crown-rump length, fetal ano-genital distance ratio and comparison of external fetal sex with internal gonads were noted at all the tested dose groups.

No treatment related gross external abnormalities were noted within any group after external examination of fetuses. The noted findings of haemorrhagic spots on the are common findings for fetuses of this species and strain.

No treatment-related abnormalities were observed during visceral examinations of fetuses at any dose. The noted findings of renal pelvic dilation, pale colored kidneys, and pale colored adrenals are anatomical variations which are common findings for fetuses of this species and strain. The observations were not dose dependent, nor were the severity of the anomaly increased with dose. This result supports the conclusion that the findings are incidental and that the test item did not produce an adverse effect on the soft tissues during fetal development.

No treatment-related abnormalities were observed during skeletal examinations of fetuses at any dose. Split thoracic/lumbar vertebral centrum; absence of proximal phalanges no. 3 and 4; absence of sternum no. 5 and 6 were recorded as malformations. Poorly ossified sternum no. 5 and 6, sacral vertebrae centrum, dumbbell shaped thoracic/lumbar/sacral vertebrae, extra ossification site on caudal vertebrae and wavy ribs were recorded as variations. The noted anomalies are common findings for fetuses of this species and strain. They did not occur in a dose-dependent pattern, nor was the severity of the anomalies increased with dose. This result supports the conclusion that the findings are incidental and that the test item, did not produce an adverse effect on the skeletal tissues during fetal development. 

For the developmental toxicity assessment, the results of the experiment support that there were notreatment relatedeffects on the parameters which assess fetal development, i.e. fetal weight, crown-rump length, fetal ano-genital distance ratio and incidences of external, soft tissue or skeletal anomalies.

The results of the experiment support the conclusion that the NOAEL [No Observed Adverse Effect Level] for the test item,6-(Isononanoylamino) hexanoic acid, compound with 2, 2′, 2″-nitrilotriethanol (1:1)for maternal and developmental toxicitywas 500 mg/kg, the high dose, as there were no effects on maternal parameters as well as fetal parameters at all the tested dose group

Based on the analogue approach, the NOAEL of the subimission substance is also considered to be 500 mg/kg bw. No effects regarding developental toxicity are expected.

Justification for classification or non-classification

Based on the available data no classification for reproductive and developmental effects is warranted according to Regulation (EC) No 1272/2008 and Council Directive 67/548/EEC.